Pfizer to shift established products earlier in Japan
This article was originally published in Scrip
Pfizer in Japan is planning to move the management of in-house mature drugs across to its established products division earlier than previously to give it more time to prepare for loss of exclusivity.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.